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Pirh2 E3 Ubiquitin Ligase Modulates Keratinocyte
Differentiation through p63
Yong-Sam Jung1, Yingjuan Qian1, Wensheng Yan1 and Xinbin Chen1
p63, a homolog of the tumor-suppressor p53, is essential for the development of the epidermis and limbs. p63 is
highly expressed in the epithelial cell layer and acts as a molecular switch that initiates epithelial stratification.
However, the mechanisms controlling p63 protein levels are still far from being fully understood. Here, we
demonstrate a regulatory protein for p63 activity. We found that Pirh2 (p53-induced RING-H2) E3 ubiquitin ligase
physically interacts with p63 and targets p63 for polyubiquitination and subsequently proteasomal degradation.
We also found that ectopic expression of Pirh2 in HaCaT cells suppresses cell proliferation. Consistent with this,
we found that along with altered expression of DNp63 protein, ectopic expression of Pirh2 promotes, whereas
knockdown of Pirh2 inhibits, keratinocyte differentiation. Collectively, our data suggest that Pirh2 has a
physiologically relevant role in keratinocyte differentiation through the posttranslational modification of p63
protein.
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INTRODUCTION
p63, a p53 ancestor gene, is expressed as the N-terminal
transactivation domain (TA)-containing and -deletion (DN)
isoforms, the former transcribed from the P1 promoter
upstream of exon 1 and the latter from the P2 promoter in
intron 3 (Yang et al., 1998). Both TA and DNp63 give rise to at
least five C-terminal alternative spliced isoforms (a, b, g, d,
and e) (Mangiulli et al., 2009). Similar to p53, TAp63 is a
transcription factor containing the N-terminal transactivation
domain, the central DNA-binding domain, and the
tetramerization domain (Yang et al., 1998). Unlike p53, TA/
DNp63a contains a C-terminal sterile a-motif domain involved
in protein–protein interaction and regulation of development
(Ponting, 1995; Yang and McKeon, 2000). It has been shown
that TAp63 exerts p53-like activities in cell cycle arrest and
cell death by regulating the expression of some p53 target
genes, including p21, Mdm2, vitamin D receptor, and Bax
(Dohn et al., 2001; McKeon, 2004; Kommagani et al., 2006;
Truong et al., 2006; Senoo et al., 2007; Guo et al., 2009).
Although DNp63 lacks the N-terminal transactivation domain
conserved in TAp63, it carries a unique transactivation
domain that consists of 13 unique amino acids for DNp63
along with the proline-rich domain (Dohn et al., 2001; King
et al., 2003; Wu et al., 2003; Helton et al., 2006). It is well
known that DNp63 has a key role in the maintenance of
proliferative potential and self-renewal of basal epidermal
cells (Yang et al., 1998; King et al., 2003; Koster et al., 2004).
Interestingly, the p63 gene is rarely mutated and even
amplified in some cancers (Hagiwara et al., 1999; Hibi
et al., 2000; Flores et al., 2005; Chikh et al., 2007),
although mutation of the p53 gene is a common event in
the majority of human cancers. Nevertheless, human patients
and mice deficient in p63 exhibit severe abnormalities of the
epidermis and limb formation, indicating that p63 has a
critical role in epidermal development (Mills et al., 1999;
Yang et al., 1999; Su et al., 2009a, b). Therefore, p63 is likely
to be regulated in a tissue-specific manner.
The p53 protein turnover is regulated by several E3
ubiquitin ligases, including Mdm2 (mouse double minute 2)
and Pirh2 (p53-induced RING-H2) (Wu et al., 1993; Leng
et al., 2003; Brooks and Gu, 2006). Interestingly, both Mdm2
and Pirh2 are RING finger E3 ligases directly regulated by p53,
and thus form a negative regulatory feedback loop with p53 to
promote p53 ubiquitination and degradation (Wu et al., 1993;
Leng et al., 2003). However, there are differences between
Mdm2 and Pirh2. For instance, Mdm2 primarily degrades p53
in unstressed cells, but Pirh2 is able to degrade p53 upon
DNA damage (Shieh et al., 1997; Prives and Hall, 1999; Maya
et al., 2001). In addition, the protein stability of p73, another
p53 family member, is regulated by Pirh2, but not by
Mdm2 (Balint et al., 1999; Ongkeko et al., 1999; Jung et al.,
2011b). Similarly, degradation of p63 protein occurs
independent of Mdm2-mediated ubiquitination (Calabro
et al., 2002; Galli et al., 2010). Therefore, it is likely that
Mdm2 specifically polyubiquitinates and degrades p53,
whereas Pirh2 is capable of regulating the protein stability of
other p53 family members.
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In this study, we found that p63 protein stability is regulated
by Pirh2. We showed that knockdown of Pirh2 upregulates,
whereas overexpression of Pirh2 downregulates, p63 expres-
sion. In addition, Pirh2 physically interacts with and polyubi-
quitinates p63, and consequently targets p63 for proteasome
degradation. Finally, we showed that Pirh2 promotes keratino-
cyte differentiation by modulating DNp63 expression. Taken
together, our findings demonstrate that Pirh2 functions as an E3
ligase for the a-isoforms of p63 and that Pirh2 has a physio-
logically relevant role in keratinocyte differentiation via post-
translational modification of p63 protein.
RESULTS
Pirh2 represses p63 expression
In addition to Mdm2, Pirh2 has been identified as an E3 ligase
regulating p53 degradation (Leng et al., 2003). Previously, we
and others showed that Pirh2 polyubiquitinates and directs
p73 for the proteasome-dependent degradation (Wu et al.,
2011; Jung et al., 2011b). As p63 shares a high degree of
sequence identities with p53 and p73 (Joerger et al., 2009), we
hypothesize that Pirh2 regulates p63 stability. To test this,
Pirh2 was transiently knocked down by Pirh2 small
interference RNA (siRNA) in RKO and HCT116 cells.
Indeed, we found that the level of TAp63a protein was
increased in Pirh2-knockdown (KD) cells (Figure 1a, p63
panel, compare lanes 2 and 4 with 1 and 3, respectively).
We would like to note that in both RKO and HCT116 cells,
TAp63a is the predominant form of p63 isoforms and can be
reliably measured by western blotting. As a positive control,
p53 was also increased upon Pirh2-KD (Figure 1a, p53 panel,
compare lanes 2 and 4 with 1 and 3, respectively). The level
of actin was measured as a loading control. Consistent with
this, we showed that the level of TAp63a protein was
gradually increased as Pirh2 was progressively knocked down
over a 3-day period in HCT116 cells (Figure 1b). Next, we
examined whether increased expression of Pirh2 leads to
decreased expression of TAp63a protein. To test this, FLAG-
tagged Pirh2 was transiently overexpressed in HCT116 and
HCT116 p53 / cells. We showed that upon ectopic
expression of Pirh2, the level of TAp63a protein was
decreased in HCT116 and HCT116 p53 / cells (Figure 1c).
Next, we wanted to examine whether Pirh2 affects DNp63
expression. To test this, Pirh2 was transiently knocked down
(Figure 1d) or overexpressed (Figure 1e) in HaCaT cells, which
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Figure 1. Knockdown of Pirh2 (p53-induced RING-H2) increases, whereas overexpression of Pirh2 decreases, p63 expression. (a) Cell lysates were prepared
from RKO (left panel) and HCT116 (right panel) cells transfected with scramble or Pirh2 small interference RNA (siRNA) to knockdown Pirh2 for 72 hours. TAp63a,
Pirh2, p53, and actin were measured with their respective antibodies. The level of TAp63a protein after normalization with actin is presented as fold change.
(b) Cell lysates were prepared from HCT116 cells transfected with Pirh2 siRNA for 0, 24, 48, and 72 hours. TAp63a, Pirh2, and actin were measured with
their respective antibodies. The level of TAp63a protein after normalization with actin is presented as fold change. (c) Western blots were prepared with
extracts from HCT116 (left panel) and HCT116 p53 / (right panel) cells that were mock-transfected or transfected with FLAG-Pirh2 for 36 hours. The blots
were analyzed as in a, except that anti-FLAG antibody was used to detect FLAG-Pirh2. The level of TAp63a protein after normalization with actin is presented
as fold change. (d) The experiment was performed as described for a, except that HaCaT cells were used for transfection. The level of DNp63a protein after
normalization with actin is presented as fold change. (e) The experiment was performed as described for c, except that HaCaT cells were used for transfection.
The level of DNp63a protein was evaluated through densitometry, and results are presented as fold change. (f) Western blots were prepared with extracts
from MCF7 cells transfected with Myc-TAp63a along with an increasing dose of FLAG-Pirh2 for 36 hours. The blots were analyzed as in b, except that
anti-FLAG antibody was used to detect FLAG-Pirh2. (g) Western blots were prepared with extracts from HaCaT cells transfected with FLAG-Pirh2 for 36 hours.
DNp63a and actin were measured with their respective antibodies. Anti-FLAG antibody was used to detect FLAG-Pirh2.
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express a high level of endogenous DNp63a (Yang et al.,
2002). Western blot analysis showed that DNp63a was
increased by Pirh2-KD but decreased by Pirh2
overexpression in HaCaT cells (Figure 1d and e, compare
lane 2 with 1). To further examine the effect of Pirh2 on p63
degradation, Myc-TAp63a was transiently expressed in MCF7
cells along with an increased dose of FLAG-Pirh2 (Figure 1f).
We showed that the levels of ectopically expressed Myc-
TAp63a were decreased by FLAG-Pirh2 in a dose-dependent
manner (Figure 1f, p63 panel). Similarly, the levels of
endogenous DNp63a were decreased (Figure 1g, p63 panel)
by FLAG-Pirh2 in a dose-dependent manner in HaCaT cells
(Figure 1g, Pirh2 panel). Interestingly, we showed that the
ability of Pirh2 to decrease the level of TAp63a and DNp63a
was blocked by treatment with MG132 proteasome inhibitor
(Figure 1f and g, compare lane 6 with 5). These data suggest
that Pirh2 targets p63 for proteasomal degradation.
Pirh2 physically associates with p63
As E3 ligase often physically interacts with its substrates, we
wanted to examine whether Pirh2 physically associates with
p63. To test this, endogenous p63 and Pirh2 in RKO and
HaCaT were immunoprecipitated by anti-p63 and anti-Pirh2,
respectively. Western blot analysis showed that endogenous
Pirh2 was detected in the TAp63a immunocomplex
(Figure 2a, top panel, lane 3). Conversely, endogenous
TAp63a was detected in the Pirh2 immunocomplex
(Figure 2a, bottom panel, lane 3). Similarly, endogenous Pirh2
was also detected in the DNp63a immunocomplex (Figure 2b,
top panel, lane 3). Conversely, endogenous DNp63a was
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Figure 2. TAp63a and DNp63a isoforms bind to Pirh2 (p53-induced RING-H2). (a, top panel) Cell extracts from RKO cells were immunoprecipitated with
anti-p63 (4A4) or control IgG. The immunocomplexes were then used to detect TAp63a and Pirh2 along with whole-cell lysates as input control. (a, bottom
panel) The experiment was performed as described for the top panel, except that immunoprecipitation (IP) was performed with anti-Pirh2 antibody. (b) The
experiments were performed as in a, except that HaCaT cells were used to immunoprecipitate DNp63a. (c) The experiments were performed as in a, except that
MIA-PaCa-2 cells were used. (d) The experiments were performed as in b, except that ME-180 cells were used. (e) The experiments were performed as in a, except
that anti-Myc was used to immunoprecipitate Myc-TAp63a (top panel) and anti-FLAG was used to immunoprecipitate FLAG-Pirh2 (bottom panel) in RKO cells
transiently transfected with Myc-TAp63a and FLAG-Pirh2. (f) The experiments were performed as in e, except that RKO cells were transiently transfected with
Myc-DNp63a and FLAG-Pirh2. (g) The experiments were performed as in a, except that anti-FLAG was used to immunoprecipitate FLAG-Pirh2 in MIA-PaCa-2
cells transiently transfected with FLAG-Pirh2. (h) The experiments were performed as in g, except that MEF-180 cells were used.
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detected in the Pirh2 immunocomplex (Figure 2b, bottom
panel, lane 3). To rule out a potential cell type–specific effect,
endogenous p63 and Pirh2 were immunoprecipitated by anti-
p63 and anti-Pirh2, respectively, in MIA-PaCa-2, which
expresses a high level of endogenous TAp63a, and ME180,
which expresses a high level of endogenous DNp63a. Again,
we showed that Pirh2 associated with TAp63a (Figure 2c) and
DNp63a (Figure 2d). To confirm this protein–protein associa-
tion between Pirh2 and TAp63a/DNp63a, FLAG-tagged Pirh2
(FLAG-Pirh2) and Myc-tagged TAp63a (Myc-p63a) or
DNp63a (Myc-DNp63a) were cotransfected into RKO cells
and then immunoprecipitated by anti-Myc and anti-
FLAG, respectively. We showed that ectopically expressed
FLAG-Pirh2 was present in the anti-Myc (TAp63a/DNp63a)
immunocomplexes (Figure 2e and f, top panel). Conversely,
ectopically expressed Myc-p63a or Myc-DNp63a was
detected in the anti-FLAG (Pirh2) immunocomplexes
(Figure 2e and f, bottom panel). In addition, FLAG-Pirh2 was
transfected into MIA-PaCa-2 and ME180 cells and then
immunoprecipitated by anti-p63 or anti-FLAG, respectively.
We showed that ectopically expressed FLAG-Pirh2 was pre-
sent in the anti-p63 (TAp63a/DNp63a) immunocomplexes
(Figure 2g and h, top panel). Conversely, endogenous TAp63a
or DNp63a was detected in the anti-FLAG (Pirh2) immuno-
complexes (Figure 2g and h, bottom panel).
Pirh2-mediated degradation of p63 occurs through a ubiquitin-
dependent pathway
To determine whether the Pirh2-mediated degradation of
p63 is ubiquitin dependent, we measured the level of
ectopically expressed p63 in ts20 cells at both the permis-
sive (35 1C) and nonpermissive (39 1C) temperatures. The
ts20 cells, a Chinese hamster lung cell line, has a thermo-
inactive ubiquitin-activating enzyme E1 (Chowdary et al.,
1994). We found that the level of TAp63a was decreased
by Pirh2 at the permissive temperature, but not much at the
nonpermissive temperature (Figure 3a, compare lanes 1
and 3 with 2 and 4, respectively). As a control, we showed
that endogenous p53 was destabilized at the permissive
temperature but not at the nonpermissive temperature
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Figure 3. Pirh2 (p53-induced RING-H2)-mediated degradation of p63 occurs though a ubiquitin-dependent proteasomal pathway. (a) ts20 cells were transiently
transfected with Myc-TAp63a along with FLAG-Pirh2 at 35 1C for 24 hours and then incubated at 35 1C or 39 1C for an additional 24 hours in the presence or
absence of MG132 (5mM). The levels of FLAG-Pirh2 and Myc-TAp63a were measured by anti-FLAG and anti-Myc antibodies, respectively. Endogenous p53 and
actin levels were measured by their respective antibodies. (b) The experiment was performed as in a, except that ts20 cells were transiently transfected with
Myc-DNp63a and FLAG-Pirh2. (c) The levels of TAp63a, FLAG-Pirh2, and actin were measured in extracts purified from MIA-PaCa-2 cells mock-transfected
or transfected with FLAG-Pirh2 followed by treatment with cycloheximide (CHX, 10mg/ml) at the indicated times (0 to 12 hours). (d) Calculated half-life of TAp63a,
using the data from c. The percentage of intensity in log10 was plotted versus time, and the t1/2 was calculated from the log10 of 50%. (e) The experiment
was performed as in c, except that HaCaT cells were used to measure the half-life of DNp63a. (f) Calculated half-life of DNp63a, using the data from c.
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(Figure 3a, compare lane 2 and 4), consistent with previous
reports that Pirh2-mediated p53 degradation is accom-
plished in a ubiquitin-dependent pathway (Chowdary
et al., 1994; Leng et al., 2003). To confirm that reduction
of TAp63a in ts20 cells is due to proteasomal degradation,
ts20 cells were treated with the proteasome inhibitor
MG132. We found that the level of TAp63a was not
decreased upon treatment with MG132 (Figure 3a, lanes
5–8), demonstrating that the degradation of TAp63a by
Pirh2 requires proteasome function. Furthermore, we
examine whether Pirh2 promotes DNp63a degradation in
ts20 cells. We showed that similar to TAp63a, DNp63a
was targeted by Pirh2 for proteasomal degradation
at the permissive temperature, which was blocked by
treatment with MG132 (Figure 3b). Finally, we examined
whether Pirh2 alters the protein half-life of TAp63a in MIA-
PaCa-2 and DNp63a in HaCaT cells. We showed that the
protein half-life of TAp63a was decreased from B7 to
4 hours (Figure 3c and d), and that of DNp63a was
decreased from B11 to 6 hours by Pirh2 overexpression
(Figure 3e and f).
Pirh2 promotes p63 polyubiquitination
To investigate whether Pirh2 can promote p63 degradation via
ubiquitination, Myc-tagged TAp63a and FLAG-tagged ubiqui-
tin were coexpressed in RKO cells with FLAG-tagged Pirh2,
Pirh2-DRING (lacks RING finger domain), or Pirh2-DN (con-
tains two substitutive mutations from Cys to Ser at amino acids
145 and 148; Figure 4a) (Jung et al., 2010). We showed that
Myc-TAp63a was detected along with slower migrating bands
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Figure 4. Pirh2 (p53-induced RING-H2) promotes TA/DNp63a polyubiquitination in vivo and in vitro. (a) Schematic presentation of Pirh2 domains (zinc (Zn)-
finger, Zn-finger domain; RING, RING-finger E3 ubiquitin ligase domain) along with location of the double point mutations and RING domain deletion. (b) Cell
lysates were prepared for 6 hours following MG132 (5mM) treatment from RKO cells transfected with Myc-TAp63a along with ubiquitin and wild-type or mutant
Pirh2. Whole-cell lysates (WCLs) were immunoprecipitated with anti-Myc antibody followed by western blotting with anti-Myc or anti-ubiquitin to detect TAp63a
ubiquitination (upper panels). The levels of ectopically expressed proteins were detected with anti-Myc and anti-FLAG, respectively (lower panels). (c) The
experiment was performed as in b, except that RKO cells were transiently transfected with Myc-DNp63a along with ubiquitin and wild-type or mutant Pirh2.
(d) In vitro ubiquitination of TAp63a was performed with glutathione S-transferase (GST)-Pirh2 and GST-Pirh2-DN along with E1, E2, and ubiquitin. The
35S-labeled reaction mixtures were separated on 8% SDS-PAGE gel and analyzed by autoradiography. (e) The experiment was performed as in d, except that
35S-labeled DNp63a was used for in vitro ubiquitination assay. The asterisk (*) represents a nonspecific band.
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by anti-Myc antibody in cells expressing Pirh2, but not Pirh2-
DRING and Pirh2-DN (Figure 4b, top p63 panel, compare
lane 4 with lanes 5 and 6). We also showed that the slow
migrating bands were recognized by anti-ubiquitin antibodies
(Figure 4b, Ub panel). This suggests that the slow migrating
bands are polyubiquitinated TAp63a. Similarly, DNp63a was
polyubiquitinated by Pirh2 (Figure 4c).
Next, we investigated whether Pirh2 directly serves as
an E3 ubiquitin ligase for p63. To test this, in vitro
ubiquitination assay was performed with 35S-labeled TAp63a
along with recombinant GST-Pirh2 or GST-Pirh2-DN. We
showed that TAp63a was polyubiquitinated by Pirh2
but not by Pirh2-DN (Figure 4d, compare lanes 3 and 4).
Similarly, we also showed that DNp63a was polyubiquitinated
by Pirh2 but not by Pirh2-DN (Figure 4e, compare lanes 3
and 4). Together, these data demonstrate that Pirh2 is capable
of polyubiquitinating TA/DNp63a and promoting TA/DNp63a
degradation.
Pirh2 promotes keratinocyte differentiation via p63
Striking defects in skin and limb development observed in p63
knockout mice suggest that p63 is essential for epidermal
homeostasis (Mills et al., 1999; Yang et al., 1999). It has been
shown that DNp63 is the dominant isoform expressed before
epidermal stratification and throughout embryonic stages
during epidermal, tooth, and hair development (Koster and
Roop, 2004; Laurikkala et al., 2006; Candi et al., 2007).
Indeed, abundant expression of DNp63 in the basal layer of
the stratified epithelia maintains the proliferative potential and
directs proper differentiation of progenitor cells (Lee and
Kimelman, 2002; Koster et al., 2004). Thus, we examined
whether Pirh2 is implicated in keratinocyte differentiation. To
test this, the HaCaT cell line was chosen, as it has been used
widely for in vitro keratinocyte differentiation (Deyrieux and
Wilson, 2007). As cell growth retardation is associated with
differentiation, we first examined whether cell proliferation is
affected by ectopic expression of Pirh2. Indeed, we found that
HaCaT cell proliferation was inhibited by ectopic expression
of Pirh2 (Figure 5a). Next, we examined whether Pirh2 has an
impact on terminal keratinocyte differentiation, which can be
measured by the formation of a cornified cell envelope (CCE;
Pillai and Bikle, 1992). We found that knockdown of Pirh2
decreased, whereas ectopic expression of Pirh2 increased,
CCE formation induced by treatment of calcium (Figure 5b
and c). In addition, we showed that knockdown of Pirh2
enhanced DNp63 expression but decreased the expression of
involucrin and filaggrin (Figure 5d). Involucrin and filaggrin
are markers commonly used to measure keratinocyte terminal
differentiation (Watt, 1983; Candi et al., 2005). Conversely,
ectopic expression of Pirh2 decreased DNp63 expression but
increased the expression of involucrin and filaggrin
(Figure 5e).
DISCUSSION
All proteins are continuously turning over, as they are being
hydrolyzed and replaced by de novo synthesis. Many proteins
are degraded by the ubiquitin-dependent proteasomal path-
way (Rock et al., 1994). In this study, we provide several lines
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Figure 5. Pirh2 (p53-induced RING-H2) promotes keratinocyte
differentiation. (a) HaCaT cells were transfected with a control vector or a
vector expressing FLAG-Pirh2. At 24 hours after transfection, appropriate cells
(5,000 cells) were seeded in six-well plates in triplicate and then cultured
for a 7-day period. The cell number was measured at the indicated time.
Error bars represent the SD from three independent experiments (*Po0.05).
OE, overexpression. (b) In all, 70–80% subconfluent HaCaT cells were
cultured with defined keratinocyte serum free medium for 24 hours, and then
transfected with scrambled small interference RNA (siRNA) or siRNA against
Pirh2 for 3 days, followed by treatment with calcium (1.5mM) for 12 days.
Cornified cell envelopes (CCEs) were analyzed as described under Materials
and Methods. (c) HaCaT cells were transfected with a control vector or a vector
expressing FLAG-Pirh2 for 24 hours, followed by treatment with calcium
(1.5mM) for 12 days. (d) The levels of Pirh2, DNp63a, involucrin (IVL),
filaggrin, and actin were measured in HaCaT cells used in b. Pirh2, DNp63a,
DNp63b, IVL, filaggrin, and actin were measured with their respective
antibodies. (e) The experiment was performed as in d, except that HaCaT cells
were transfected with a control vector or a vector expressing FLAG-Pirh2,
followed by treatment with calcium (1.5 mM) for 12 days.
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of evidence to support the fact that Pirh2 targets both TAp63a
and DNp63a proteins for ubiquitin-dependent proteasomal
degradation. First, Pirh2 physically binds to p63. Second,
Pirh2 promotes p63 ubiquitination through its E3 ligase
activity. Third, Pirh2 promotes p63 degradation in a
ubiquitin-dependent manner. Finally, Pirh2 promotes
keratinocyte differentiation via degradation of DNp63a.
Since its discovery as homologs of the p53 tumor suppres-
sor, p63 and p73 have gained tremendous attention and have
been intensively investigated. However, although p63 and
p73 perform p53-like functions, they are not classic Knudson-
type tumor suppressors, as they are key regulators in devel-
opment (Melino et al., 2002). This indicates that p63 and p73
are not just redundant family proteins for p53. Because of the
functional diversity among p53 family members, it is not
surprising that p53, p63, and p73 are differentially regulated.
For example, p53 stability is primarily regulated by the
ubiquitin–proteasome degradation pathway via E3 ubiquitin
ligases, including RING finger E3 ligases (Mdm2, Pirh2, and
COP1) and HECT-domain E3 ligases (E6-AP and Arf-BP1) (Lee
and Gu, 2010). Degradation of p63 protein is mediated by
Dlx3 (Di Costanzo et al., 2009), RACK1 (receptor for protein
kinase C) (Li et al., 2009), and HECT domain–containing E3
ligases, including ITCH (Rossi et al., 2006) and WWP1 (Li
et al., 2008). p73 ubiquitination has been shown to be
regulated by ITCH (Rossi et al., 2005), FBXO45 (an F-box
protein) (Peschiaroli et al., 2009), and NEDL2 (a NEDD4-
related HECT domain–containing E3 ligase) (Miyazaki et al.,
2003). To date, E3 ligases that can target all the members of
the p53 family have not been reported. Here, we found that
overexpression of Pirh2 decreases, whereas knockdown of
Pirh2 increases, the level of TA/DNp63a protein (Figure 1).
In addition, we showed that Pirh2 physically associates with
TA/DNp63a (Figure 2), promoting its polyubiquitination and
degradation through proteasome (Figures 3 and 4). Together,
we concluded that p63 is a substrate for Pirh2 E3 ubiquitin
ligase. Previously, we and others showed that Pirh2 promotes
p53/p73 protein turnover via polyubiquitination. Thus, for the
first time, to our knowledge previously unreported, we
showed that Pirh2 is a common E3 ubiquitin ligase for p53,
p63, and p73.
The epidermis is the self-renewing stratified epithelium on
the outermost layer of the skin. A variety of genes, such as
involucrin, loricrin, and keratins, are involved in skin forma-
tion as a barrier against the environment (Candi et al., 2005).
DNp63a is not only the main isoform essential for epidermal
development during embryogenesis, but also controls
epithelial cell differentiation in the basal layer of the
epidermis in adults (King et al., 2003; Koster and Roop,
2004). DNp63a is highly expressed in basal epithelial cells,
and downregulation of DNp63a initiates differentiation (Yang
et al., 1998; King et al., 2003; Koster et al., 2004). However,
upstream regulator of DNp63a during differentiation is not
clear. In this study, we found that overexpression of Pirh2
significantly inhibits cell proliferation in HaCaT cells
(Figure 5a). Consistent with this, it was previously showed
that depletion of DNp63 reduces cell viability in head and
neck squamous carcinoma epithelial cells (Rocco et al.,
2006). Moreover, we found that depletion of Pirh2
decreased, whereas overexpression of Pirh2 increased, the
level of CCE formation (Figure 5b and d). This suggests
that Pirh2 is an important regulator in epithelial development.
As p63 is regulated by several E3 ligases, including
ITCH (Rossi et al., 2006), Mdm2/Mdmx (Wang et al., 2001;
Calabro et al., 2002), WWP1 (Li et al., 2008), and SCF TrCP1
(Gallegos et al., 2008), how a proper level of p63 isoforms is
maintained during skin development and/or in response to
DNA damage needs to be examined. In addition, knowledge
of the upstream signal that modulates Pirh2-mediated p63
degradation during epithermal differentiation is of great
interest for future studies.
As a common regulator of p53 family members, it is
reasonable to speculate that Pirh2 has a role in tumorigenesis.
Indeed, evidence showed that Pirh2 may act as an oncopro-
tein or tumor suppressor in different types of human cancers
(Jung et al., 2012). Downregulation of tumor-suppressor
proteins including p53, p73, and p27 may contribute to
tumor progression in cancers with high Pirh2 expression
(Duan et al., 2004, 2006, 2007). However, upregulation of
oncogenic c-Myc leads to tumor formation in Pirh2 knockout
mice and in cancers with low Pirh2 expression (Hakem et al.,
2011). Previously, we showed that Pirh2 inhibits DNA
polymerase-Z (PolH) activity by degrading PolH through the
20S proteasome or promoting PolH monoubiquitination (Jung
et al., 2010, 2011a). PolH is critical in translesion DNA
synthesis, and loss of PolH results in early onset of skin tumor
formation upon UV-induced replication stress in PolH-
knockout mice (Ohkumo et al., 2006). In addition, Pirh2 is
associated with keratin-8/18, which is abundantly expressed
in epithelial cells, to regulate UV-induced cell death through
modulating mitochondrial distribution (Duan et al., 2009).
Here, we showed that DNp63a is targeted by Pirh2 for
proteasomal degradation. Interestingly, except its essential
role in skin development and in maintaining epidermal
homeostasis in adults, elevated expression of DNp63a is
correlated with multiple epithelial cancers (Candi et al.,
2007). Moreover, it has been shown that wild-type p53
mediates the suntanning response (Cui et al., 2007). Taken
together, it is likely that Pirh2 has a role in skin carcinogenesis
through its targets, and future studies deciphering how Pirh2
targets are involved in skin carcinogenesis will provide
important clues for skin cancer treatment.
MATERIALS AND METHODS
Cell culture and plasmids
RKO, MCF7, HaCaT, the temperature-sensitive ts20, HCT116, MIA-
PaCa-2, ME180, and HCT116 p53 / were maintained in DMEM
supplemented with 10% fetal bovine serum and antibiotics. Human
full-length Pirh2, Pirh2-DN (an E3 ligase defective mutant), and Pirh2-
DRING (the RING finger domain deletion mutant) were used as
previously described (Jung et al., 2010). All Pirh2 proteins were
N-terminally FLAG-tagged as previously described (Jung et al., 2010).
Complementary DNAs encoding TAp63a and DNp63a were
N-terminally Myc-tagged as previously described (Gaiddon et al.,
2001). FLAG-tagged Ubiquitin expression vector in pcDNA3 was
used as previously described (Jung et al., 2010).
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Antibodies
Antibodies used in this study were as follows: rabbit polyclonal anti-
Pirh2 (Bethyl Laboratories, Montgomery, TX), mouse monoclonal
anti-p63 (Santa Cruz Biotechnology, Santa Cruz, CA), mouse mono-
clonal anti-Involucrin (Santa Cruz Biotechnology), mouse monoclo-
nal Filaggrin (Santa Cruz Biotechnology), mouse monoclonal anti-p53
antibodies (a mixture of DO-1, PAb1801, PAb240, and PAb421)
derived from hybridoma’s supernatant, mouse monoclonal anti-
ubiquitin (Santa Cruz Biotechnology), rabbit polyclonal anti-Myc
(Abcam, Cambridge, MA), mouse monoclonal anti-FLAG (Sigma),
and rabbit polyclonal anti-actin (Sigma, La Jolla, CA).
Immunoprecipitation–western blot analysis
The immunoprecipitation experiment was carried out as previously
described (Jung et al., 2008). Briefly, cells were washed with
phosphate-buffered saline, lysed in mammalian lysis buffer (50 mM
Tris-Cl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, and
0.4 mM phenylmethylsulfonyl fluoride (PMSF)), sonicated, and cleared
by centrifugation. Cell lysates (300–500mg of total proteins) were
incubated for 4 hours at 4 1C with the indicated antibodies coupled to
the protein A/G-agarose beads (Sigma) and then washed with
mammalian lysis buffer. Immunoprecipitated protein complexes and
whole-cell lysates were subjected to SDS-PAGE. For each set, input
controls were run (5% of whole-cell lysates used for immuno-
precipitation). IgG antibody was used as a negative control for each
immunoprecipitation assay. Immunoblots were visualized by
SuperSignal West Femto Chemiluminiscent detection reagents
(Pierce, Rockford, IL).
Small interference RNA
Scramble and Pirh2 siRNA (sense 50-CCAACAGACUUGUGAAGAA-
dTdT-30 and antisense 50-UUCUUCACAAGUCUGUUGG-dTdT-30)
were purchased from Dharmacon (Lafayette, CO) (Jung et al., 2011a).
The siRNA duplex was introduced into cells using SilentFect
(Bio-Rad, Hercules, CA) according to the manufacturer’s protocol.
Cells were harvested at the indicated times after transfection for
further experiments.
GST fusion protein preparation
Glutathione S-transferase (GST)–tagged Pirh2 and Pirh2-DN were
expressed by pGEX-4T-3 (Amersham Pharmacia Biotech, Pistcat-
away, NJ). The recombinant GST-tagged proteins were purified as
described previously (Jung et al., 2008). Briefly, the GST fusions of
Pirh2 and Pirh2-DN were expressed in E. coli BL21 (DE3)
(Novagene, Madison, WI) upon induction with 0.5 mM IPTG for
4 hours at 37 1C. Bacterial cells were harvested and then
resuspended in GST lysis buffer (200 mM Tris-Cl, pH 8.0, 0.5 M
NaCl, 100 mM EDTA, 0.1% Triton X-100, and 0.4 mM PMSF).
Subsequently, cell lysates were sonicated and clarified by centri-
fugation. GST fusion proteins were purified using glutathione-
Sepharose beads (Amersham Pharmacia Biotech) according to the
manufacturer’s protocol.
Ubiquitination assay
In vivo ubiquitination assay was performed as described (Leng et al.,
2003). RKO cells were transfected with the indicated plasmids and
treated with 5mM MG132 for 6 hours before harvest. Cell lysates were
immunoprecipitated with anti-Myc antibody followed by western blot
analysis with anti-Myc and anti-Ubiquitin antibodies to detect p63
ubiquitination.
In vitro ubiquitination assay using recombinant GST fusion Pirh2
proteins was performed as described (Jung et al., 2011a). The
35S-labeled TAp63a and DNp63a proteins were mixed with GST-
Pirh2 or -Pirh2-DN and then incubated on ice for 1 hour to form
Pirh2/p63 protein complexes. The complexes were added to
ubiquitination buffer containing E1, E2, and ubiquitin, and
incubated at 30 1C for 2 hours. Finally, the reaction mixtures were
separated on SDS-PAGE and analyzed by autoradiography. E1, E2,
and ubiquitin were purchased from Boston Biochem (Cambridge,
MA). The 35S-labeled p63 was produced by the TNT T7-coupled
reticulocyte lysates system (Promega, Madison, WI).
Cell proliferation assay
To evaluate the calcium-induced differentiation effect on proliferation
of HaCaT cells, cell proliferation assay was performed. HaCaT
cells were transfected with control pcDNA3 vector or pcDNA3-2X-
FLAG-Pirh2 for 24 hours, and then an appropriate number of
cells were cultured in six-well plates in triplicate. Cells were
cultured in calcium-containing medium (1.5 mM) over a 7-day
period. Cells were harvested and counted at indicated times. All
values are given as mean±SD. Statistical comparisons were made by
Student’s t-test. A P-value of o0.05 was considered statistically
significant.
CCE assay
CCEs were analyzed as described previously (Zhang et al., 2010;
Qian et al., 2011). Briefly, cells were harvested and resuspended in
1.1 ml of phosphate-buffered saline containing 2 mM EDTA, and 100-
ml aliquots were counted for the total number of cells. The remaining
cells were centrifuged and resuspended in dissociation buffer (2%
SDS, 20 mM dithiothreitol, 5 mM EDTA, and 0.1 M Tris-Cl, pH 8.5) and
heated for 5 minutes. After cooling, insoluble CCEs were harvested
and resuspended in 100ml of phosphate-buffered saline and counted
with a hematocytometer. The data were measured as CCEs/total
cells 100. The fold change in relative CCE is a product of CCEs
induced by Pirh2 overexpresson or knockdown, divided by that
induced by control.
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